Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention a current or expected order book or pending orders for Vijaya Diagnostic Centre Limited. Focus is on expansion plans: adding 10 new hub centers in the next 2 years, including 4 to 5 hubs in Pune and others in east and core geographies. Locations for 6 hubs have been finalized with leases signed; a few more to be finalized soon. Emphasis is on operational scaling and building capacity rather than order backlog. Capital expenditure of INR 200-220 crores planned mostly for new hubs and spokes. Management prioritizes team building and skill development to

Any current/future new fundraising through debt or equity?

No current need for raising debt as the company has a healthy treasury of around INR185 crore. Expected free cash flow of INR170-190 crores annually supports upcoming capex requirements. Planned capex of INR200-220 crores for new centers in the next 2 years will be funded largely through internal accruals and cash reserves. Debt raising will only be considered if inorganic acquisitions are made, but no such plans currently. Equity fundraising is not mentioned as a requirement currently. Management emphasizes operational scaling and talent acquisition as key constraints rather than capital avai

Any current/future capex/capital investment/strategic investment?

Planned capital expenditure (capex) of INR 200 to 220 crores over the next 2 years. Majority of capex aimed at adding about 10 new hubs, with 4 to 5 in Pune and the rest in eastern and core geographies. INR 120 crores of the capex expected to be spent in the Pune region, including one flagship hub with PET CT, gamma camera, and state-of-the-art facilities. Additional investment planned for adding spokes linked to these hubs, supporting network expansion. Some capex reserved for adding new modalities and replacing old equipment (replacement capex of around INR 10-15 crores, over and above INR 2

Future growth expectations in sales/revenue/volumes?

Company expects low single-digit volume growth (around 10-12%) in existing hubs limited by capacity constraints. New hubs opening expected to drive faster growth with potential for low double-digit revenue growth once new capacity is added. PH Pune business expected to triple revenue in 4-5 years, with 5 new hubs starting over 2 years. Organic revenue growth excluding PH Pune around 18.5% year-on-year reported, driven primarily by volume growth (~17%). Hyderabad core region showing healthy double-digit growth (~13-14%) in revenue and 11-12% in volume. Tier 2 and new geographies showing higher

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims for a **low double-digit volume growth** in existing centers, constrained mainly by capacity. With **new hubs opening (5 hubs planned 2-3 in FY25 and 2 in early FY26)**, faster growth (double-digit) is expected once they commence operations. **Hub centers typically breakeven within 3 quarters to 1 year** after opening. **PH Pune business revenue (~INR45-50 crores) is expected to triple over 4-5 years** as hubs mature. EBITDA margins are expected to remain **around 40% on core business**, with slight impact (±1%) during hub expansions. Expansion capex of around **INR200-220 cro

Vijaya Diagnost.Q4 FY24Healthcare Services

Vijaya Diagnost. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,428P/E: 83.2Market Cap: ₹15.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Company expects low single-digit volume growth (around 10-12%) in existing hubs limited by capacity constraints.
New hubs opening expected to drive faster growth with potential for low double-digit revenue growth once new capacity is added.
PH Pune business expected to triple revenue in 4-5 years, with 5 new hubs starting over 2 years.
Organic revenue growth excluding PH Pune around 18.5% year-on-year reported, driven primarily by volume growth (~17%).
Hyderabad core region showing healthy double-digit growth (~13-14%) in revenue and 11-12% in volume.
Tier 2 and new geographies showing higher volume growth, around 30-40%, due to capacity expansion.
Plans to add around 10 hubs in 2 years, with 4-5 in Pune for faster-market growth.
Overall revenue growth driven both by footfall increases and modest price/mix changes (1-2%).

Margin guidance

Category 3

The company aims for a low double-digit volume growth in existing centers, constrained mainly by capacity.
With new hubs opening (5 hubs planned 2-3 in FY25 and 2 in early FY26), faster growth (double-digit) is expected once they commence operations.
Hub centers typically breakeven within 3 quarters to 1 year after opening.
PH Pune business revenue (~INR45-50 crores) is expected to triple over 4-5 years as hubs mature.
EBITDA margins are expected to remain around 40% on core business, with slight impact (±1%) during hub expansions.
Expansion capex of around INR200-220 crores over 2 years, mainly internally funded, supporting growth.
The company targets to maintain robust EBITDA and PAT growth in line with revenue growth of ~18-28% YoY seen recently.
Plans to leverage digital initiatives and improve customer experience to sustain growth momentum.

See what Vijaya Diagnost. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No current need for raising debt as the company has a healthy treasury of around INR185 crore.
Expected free cash flow of INR170-190 crores annually supports upcoming capex requirements.
Planned capex of INR200-220 crores for new centers in the next 2 years will be funded largely through internal accruals and cash reserves.
Debt raising will only be considered if inorganic acquisitions are made, but no such plans currently.
Equity fundraising is not mentioned as a requirement currently.
Management emphasizes operational scaling and talent acquisition as key constraints rather than capital availability.

Order book

Yes

The transcript does not explicitly mention a current or expected order book or pending orders for Vijaya Diagnostic Centre Limited.
Focus is on expansion plans: adding 10 new hub centers in the next 2 years, including 4 to 5 hubs in Pune and others in east and core geographies.
Locations for 6 hubs have been finalized with leases signed; a few more to be finalized soon.
Emphasis is on operational scaling and building capacity rather than order backlog.
Capital expenditure of INR 200-220 crores planned mostly for new hubs and spokes.
Management prioritizes team building and skill development to support growth; capacity constraints affect pace of expansion.
No specific details given on pending orders or orderbook in the provided content.

See what Vijaya Diagnost. management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned capital expenditure (capex) of INR 200 to 220 crores over the next 2 years.
Majority of capex aimed at adding about 10 new hubs, with 4 to 5 in Pune and the rest in eastern and core geographies.
INR 120 crores of the capex expected to be spent in the Pune region, including one flagship hub with PET CT, gamma camera, and state-of-the-art facilities.
Additional investment planned for adding spokes linked to these hubs, supporting network expansion.
Some capex reserved for adding new modalities and replacing old equipment (replacement capex of around INR 10-15 crores, over and above INR 220 crores).
Investments include upgrading IT systems and digital initiatives (~INR 2-3 crores annually).
Growth-funded primarily from internal accruals and existing cash reserves; no anticipated debt raising required.
Potential inorganic acquisitions considered if suitable opportunities arise.

Track Vijaya Diagnost. — get its next earnings analysis in your feed

How does Vijaya Diagnost. rank vs peers in Healthcare Services?

Pro feature

ThisVijaya Diagnost.

Rev 3Mar 3

See where Vijaya Diagnost. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Vijaya Diagnost. rank in Healthcare Services?

Compare Vijaya Diagnost. against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Vijaya Diagnost. Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Vijaya Diagnost. rank in Healthcare Services?

Continue your research

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season